Literature DB >> 18551245

Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure.

Scott O Grebe1, Marc Borrmann2, Alexander Altenburg3, Ulrich Wesselman4, Dietmar Hein2, Patrick Haage3.   

Abstract

Nephrogenic systemic fibrosis (NSF) is a rare disorder in patients with chronic kidney disease characterized by an increased tissue deposition of collagen. Its pathogenesis remains unclear. Prior studies indirectly suggested a possible impact of chronic inflammation and accelerated atherosclerosis--a common feature in kidney diseased patients--whereas recent data focused almost exclusively on gadolinium (Gd)-based MR contrast agents. Usually NSF develops a maximum of 2-3 months after Gd. Longer intervals have not yet been described. Therefore, we present the first case with an extraordinary long time course in terms of chronic inflammation. A 52-year-old Caucasian woman with end-stage renal disease was admitted to our hospital with progressive muscle weakness and skin induration resulting in growing immobility. Her past medical history revealed a secondary HPT, multiple vascular complications, a seronegative rheumatoid arthritis, and a pituitary gland adenoma. The latter conditions led to multiple MR examinations with Gd-based contrast agents, the last one more than 4 years ago. Numerous laboratory tests were performed including ESR, CRP, intact parathyroid hormone (iPTH), serum ferritin, cyclic-citrullinated peptide antibodies (CCP), ANA, ANCA, immunoelectrophoresis, and serology for hepatitis as well as human immunodeficiency virus. Eventually a skin biopsy of her left thigh was obtained. The laboratory investigation showed persistently elevated levels of CRP, ESR, serum ferritin, and iPTH, whereas all other parameters were inconspicuous. The hisology displayed typical signs of nephrogenic systemic fibrosis. NSF can occur at any time after Gd exposure in the long term. Gd is a necessary, but not the sole cause of NSF. Certain other cofactors such as chronic inflammation and accelerated atherosclerosis seem to be involved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551245     DOI: 10.1007/s10157-008-0063-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  8 in total

1.  Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy.

Authors:  Sundararaman Swaminathan; Iftikhar Ahmed; James T McCarthy; Robert C Albright; Mark R Pittelkow; Noel M Caplice; Matthew D Griffin; Nelson Leung
Journal:  Ann Intern Med       Date:  2006-08-01       Impact factor: 25.391

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

Review 4.  Nephrogenic systemic fibrosis: an update.

Authors:  Shawn E Cowper; Philip J Boyer
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 5.  Gadolinium deposition in nephrogenic fibrosing dermopathy.

Authors:  Alan S Boyd; John A Zic; Jerrold L Abraham
Journal:  J Am Acad Dermatol       Date:  2006-11-15       Impact factor: 11.527

Review 6.  Atherosclerosis in dialyzed patients.

Authors:  Eberhard Ritz
Journal:  Blood Purif       Date:  2004       Impact factor: 2.614

Review 7.  New insights into nephrogenic systemic fibrosis.

Authors:  Sundararaman Swaminathan; Sudhir V Shah
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

8.  Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2006-10-24       Impact factor: 5.315

  8 in total
  4 in total

1.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

Review 2.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

3.  An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.

Authors:  Bin Zhang; Long Liang; Wenbo Chen; Changhong Liang; Shuixing Zhang
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

4.  In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform.

Authors:  Marios Spanakis; Kostas Marias
Journal:  In Silico Pharmacol       Date:  2014-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.